301. Macular dystrophy Clinical trials / Disease details


Clinical trials : 46 Drugs : 42 - (DrugBank : 11) / Drug target genes : 9 - Drug target pathways : 67

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00420602
(ClinicalTrials.gov)
September 21, 200710/1/2007DHA Supplementation in Patients With STGD3Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3Dominantly Inherited Stargardt's Disease (STGD3)Dietary Supplement: Over the counter DHA/EPA dietary supplementationUniversity of UtahNULLCompleted18 Years105 YearsAll11N/AUnited States
2NCT00060749
(ClinicalTrials.gov)
May 5, 20039/5/2003Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular DystrophyInvestigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular DystrophyMacular DegenerationDrug: Docosahexaenoic Acid (DHA) Dietary SupplementNational Eye Institute (NEI)NULLCompletedN/AN/AAll22Phase 1United States